Skip to Content

    Sales of multiple sclerosis drug Tecfidera helped treat this pharmaceutical firm to a hale 2014 (though recent results missed targets).

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Location
    Cambridge, MA
    Industry
    Pharmaceuticals
    Sector
    Health Care
    Fortune 500 Rank298
    Fortune 500 Profilehttp://fortune.com/fortune500/biogen-298/
    Current Streak1
    Years on List1
    CEO
    George A. Scangos
    Websitehttp://www.biogen.com

    Revenue, Net Income

    Revenue Past Four Quarters10,129
    Net Income Past Four Quarters3,277

    Growth Rates

    EPS 3 yr Annual Growth Rate35%
    Rev 3 yr Annual Growth Rate26%
    Total Return 3 yr Annual Rate41%
    Beat S&P 3 yr Total Return?
    yes

    Rank

    EPS Growth Rank69
    Revenue Growth Rank63
    Total Return Rank
    53